The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1451230
This article is part of the Research Topic Treatment Response and Resistance to Targeted Therapies for NSCLC View all 14 articles
Targeted Therapy of Non-Small Cell Lung Cancer: Mechanisms and Clinical trials
Provisionally accepted- 1 Sichuan Cancer Hospital, Chengdu, China
- 2 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
Lung cancer is a leading cause of cancer-related deaths globally, and traditional chemotherapy has limited efficacy in treating advanced non-small cell lung cancer (NSCLC). In recent years, the prognosis for patients with NSCLC has significantly improved due to the development of new treatment modalities, including targeted therapies. Targeted therapies utilize monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), or small molecule tyrosine kinase inhibitors (TKIs) directed against specific mutated genes such as EGFR and ALK. The development of these drugs has deepened our understanding of NSCLC and improved treatment outcomes for patients. This review aims to summarize the mechanisms and current status of targeted therapy for NSCLC, discuss strategies to overcome acquired resistance, and address current challenges in the field.
Keywords: NSCLC, target therapy, TKIs, monoclonal antibodies, Antibody-drug conjugate
Received: 18 Jun 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 Yu, Yang, Long, tao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Le Yu, Sichuan Cancer Hospital, Chengdu, China
Bin Liu, Sichuan Cancer Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.